scholarly journals Initial experience of video-assisted thoracic surgery lobectomy after neoadjuvant chemotherapy plus toripalimab in a patient with locally advanced non-small cell lung cancer: a case report

2022 ◽  
Vol 17 (1) ◽  
Author(s):  
Wei Li ◽  
Chunbo Zhai ◽  
Jianpeng Che ◽  
Weiqian Wang ◽  
Bingchun Liu
Keyword(s):  
Lung Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Thoracic Surgery ◽  
Small Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Advanced Nsclc ◽  
Locally Advanced ◽  
Small Cell ◽  
Small Cell Lung ◽  
Locally Advanced Nsclc

Abstract Background Immune checkpoint inhibitors were used for patients with advanced non-small cell lung cancer (NSCLC) more and more frequently and the effects were thrilling. Toripalimab as a new immune checkpoint inhibitor has been shown to be effective in patients with advanced NSCLC. However, data regarding the safety and feasibility of surgical resection after treatment with toripalimab for NSCLC remain scarce. Here, we present a case with locally advanced NSCLC that received video-assisted thoracic surgery (VATS) lobectomy after treatment with toripalimab in combination with chemotherapy. Case presentation A 62-year-old male patient with a history of coronary artery stenting operation for two times was found a 3.4 × 3.2 cm cavity mass in the upper lobe of the left lung and enlarged left hilar and mediastinal lymph nodes. Pathological results identified squamous cell carcinoma. The patient was diagnosed with a locally advanced NSCLC and received VATS left upper lobectomy and lymph node dissection after neoadjuvant chemotherapy plus toripalimab for 3 cycles. The postoperative pathological results showed complete tumor remission. Short-term follow-up results were excellent, and long-term results remain to be revealed. Conclusions Our preliminary results showed that the use of neoadjuvant toripalimab and chemotherapy for the locally advanced NSCLC before surgical resection is safe and feasible.

scholarly journals Initial Experience of Video-Assisted Thoracic Surgery Lobectomy After Neoadjuvant Chemotherapy Plus Toripalimab in a Patient with Locally Advanced Non-Small Cell Lung Cancer: A Case Report

2021 ◽  
Author(s):  
Wei Li ◽  
Chunbo Zhai ◽  
Jianpeng Che ◽  
Weiqian Wang ◽  
Bingchun Liu
Keyword(s):  
Lung Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Thoracic Surgery ◽  
Small Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Advanced Nsclc ◽  
Locally Advanced ◽  
Small Cell ◽  
Small Cell Lung ◽  
Locally Advanced Nsclc

Abstract Background: Immune checkpoint inhibitors were used for patients with advanced non-small cell lung cancer (NSCLC) more and more frequently and the effects were thrilling. Toripalimab as a new immune checkpoint inhibitor has been shown to be effective in patients with advanced NSCLC. However, data regarding the safety and feasibility of surgical resection after treatment with toripalimab for NSCLC remain scarce. Here, we present a case with locally advanced NSCLC that received video-assisted thoracic surgery (VATS) lobectomy after treatment with toripalimab in combination with chemotherapy.Case presentation: A 62-year-old male patient with a history of coronary artery stenting operation for two times was found a 3.4 × 3.2cm cavity mass in the upper lobe of the left lung and enlarged left hilar and mediastinal lymph nodes. Pathological results identified squamous cell carcinoma. The patient was diagnosed with a locally advanced NSCLC and received VATS left upper lobectomy and lymph node dissection after neoadjuvant chemotherapy plus toripalimab for 3 cycles. The postoperative pathological results showed complete tumor remission. Short-term follow-up results were excellent, and long-term results remain to be revealed.Conclusions: Our preliminary results showed that the use of neoadjuvant toripalimab and chemotherapy for the locally advanced NSCLC before surgical resection is safe and feasible.

scholarly journals Initial Experience of Video-assisted Thoracic Surgery Lobectomy After Neoadjuvant Chemotherapy Plus Toripalimab in a Patient With Locally Advanced Non-small Cell Lung Cancer: A Case Report

2021 ◽  
Author(s):  
Chunbo Zhai ◽  
Wei Li ◽  
Jianpeng Che ◽  
Weiqian Wang ◽  
Bingchun Liu
Keyword(s):  
Lung Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Thoracic Surgery ◽  
Small Cell Lung Cancer ◽  
Surgical Resection ◽  
Advanced Nsclc ◽  
Locally Advanced ◽  
Small Cell ◽  
Small Cell Lung ◽  
Locally Advanced Nsclc

Abstract BackgroundImmune checkpoint inhibitors were used for patients with advanced non-small cell lung cancer (NSCLC) more and more frequently and the effects were thrilling. Toripalimab as a new immune checkpoint inhibitor has been shown to be effective in patients with advanced NSCLC. However, data regarding the safety and feasibility of surgical resection after treatment with toripalimab for NSCLC remain scarce. Here, we present a case with locally advanced NSCLC that received video-assisted thoracic surgery (VATS) lobectomy after treatment with toripalimab in combination with chemotherapy. Case Presentation A 62-year-old male patient with a history of coronary artery stenting operation for two times was found a 3.4 × 3.2cm cavity mass in the upper lobe of the left lung and enlarged left hilar and mediastinal lymph nodes. Pathological results identified squamous cell carcinoma. The patient was diagnosed with a locally advanced NSCLC and received VATS left upper lobectomy and lymph node dissection after neoadjuvant chemotherapy plus toripalimab for 3 cycles. The postoperative pathological results showed complete tumor remission. Short-term follow-up results were excellent, and long-term results remain to be revealed. ConclusionsOur preliminary results showed that the use of neoadjuvant toripalimab and chemotherapy for the locally advanced NSCLC before surgical resection is safe and feasible.

scholarly journals Surgery after chemoradiotherapy in patients with stage III (N2 or N3, excluding T4) non-small cell lung cancer: a systematic review

2019 ◽  
Vol 26 (3) ◽  
Author(s):  
A. Swaminath ◽  
E. T. Vella ◽  
K. Ramchandar ◽  
A. Robinson ◽  
C. Simone ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Advanced Nsclc ◽  
Locally Advanced ◽  
Small Cell ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Locally Advanced Nsclc

Background: Chemoradiation with curative intent is considered standard of care in patients with locally-advanced, stage III non-small cell lung cancer (NSCLC). However, there may be patients with stage III (N2 or N3, including T4) NSCLC who may be eligible for surgery. The objective of this systematic review was to investigate the efficacy of surgery after chemoradiotherapy compared with chemoradiotherapy alone in patients with locally-advanced NSCLC.Methods: MEDLINE, EMBASE, and PubMed were searched for randomized controlled trials (RCTs) comparing surgery after chemoradiotherapy versus chemoradiotherapy alone in patients with stage III (N2 or N3, excluding T4) NSCLC.Results: Three included RCTs consistently found no statistically significant difference in overall survival between patients with locally-advanced NSCLC who received surgery and chemoradiotherapy or chemoradiotherapy alone. Only one RCT found a significantly longer progression-free survival (PFS) in patients treated with chemoradiation and surgery (HR, 0.77; 95% confidence interval [CI], 0.62 to 0.96). In a post-hoc analysis of the same trial, the rate of overall survival was higher in the surgical group compared with patients matched in the chemoradiation-alone group if a lobectomy was performed (p=0.002), but not when a pneumonectomy was performed. Furthermore, fewer treatment-related deaths occurred among patients who received lobectomy compared with pneumonectomy.Conclusion: For patients with locally-advanced NSCLC, the benefits of surgery following chemoradiation were uncertain. Surgery after chemoradiation for patients who do not require a pneumonectomy may be an option.

Lung Cancer in the Elderly

2007 ◽  
Vol 25 (14) ◽  
pp. 1898-1907 ◽  
Author(s):  
Cesare Gridelli ◽  
Corey Langer ◽  
Paolo Maione ◽  
Antonio Rossi ◽  
Steven E. Schild
Keyword(s):  
Lung Cancer ◽  
Elderly Patients ◽  
Small Cell Lung Cancer ◽  
Advanced Nsclc ◽  
Locally Advanced ◽  
The Elderly ◽  
Small Cell ◽  
Small Cell Lung ◽  
Younger Patients ◽  
Locally Advanced Nsclc

PurposeElderly patients often have comorbidities and other characteristics that make the selection of treatment daunting.MethodsWe have reviewed the available evidence in the literature to gauge the results of therapy for elderly lung cancer patients.ResultsThe beneficial results achieved with adjuvant chemotherapy in the general population with early non–small-cell lung cancer (NSCLC) cannot be automatically extrapolated to the elderly, who are at higher risk of toxicity. Retrospective analyses of combined chemoradiotherapy in locally advanced NSCLC patients suggest equivalent therapeutic benefit for younger and older patients, despite heightened toxicity. There have been no elderly-specific phase III trials for locally advanced NSCLC. For advanced NSCLC, on the basis of evidence-based data, single-agent chemotherapy remains the standard of care for nonselected elderly patients. However, retrospective analyses suggest that the efficacy of platinum-based combination chemotherapy is similar in fit older and younger patients, with increased but acceptable toxicity for elderly patients. In limited-disease small-cell lung cancer (SCLC), sequential chemoradiotherapy is clearly less toxic compared with a standard concurrent approach, but our assessment of treatment is hindered by the absence of prospective elderly-specific trials. Although prophylactic cranial irradiation has emerged as a standard strategy, it should be omitted in patients with cognitive impairment. In extensive SCLC, etoposide in combination with either cisplatin or carboplatin has emerged as standard treatment; hematopoietic support may be necessary.ConclusionWith the exception of advanced NSCLC, prospective elderly-specific studies are lacking. Available data suggest that outcomes in the fit elderly mirror results observed in younger patients, although toxicity is generally worse.

Efficacy comparison of concurrent chemoradiotherapy with nedaplatin and cisplatin in inoperable locally-advanced non-small cell lung cancer

2020 ◽  
Vol 20 (5) ◽  
pp. 355-376
Author(s):  
Yongli WU ◽  
◽  
Kuantang CHEN ◽  
Jun WANG
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Concurrent Chemoradiotherapy ◽  
Advanced Nsclc ◽  
Locally Advanced ◽  
High Energy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Locally Advanced Nsclc

Objective： To compare the efficacy and safety of concurrent chemoradiotherapy with nedaplatin and cisplatin in inoperative locally-advanced non-small cell lung cancer（NSCLC）.Methods： Eighty patients with locally-advanced NSCLC treated in Guanyun County People’s Hospital，Lianyungang，Jiangsu Province，from January 2015 to January 2019 were enrolled as study subjects，and were randomly divided into the nedaplatin group and the cisplatin group，each consisting of 40 patients.The patients in the 2 groups were treated with linear accelerator 6 MV high energy X-ray and 3D-CRT，5 times a week for a succession of 6 weeks，with a total dosage of 55-66 Gy.Then，the patients were given paclitaxel（155 mg/m2） intravenously for 3 hours in the first day after radiotherapy，and the patients in the cisplatin group were treated with cisplatin（80 mg/m2） intravenously for 3 to 4 days，and the patients in the nedaplatin group were given nedaplatin（80 mg/m2） intravenously also for 3 to 4 days.The efficacy，the levels of such serum tumor markers as carcinoembryonic antigen（CEA），carbohydrate antigen 125（CA125），neuron specific enolase（NSE） and cytokeratin fragment antigen 21-1（CYFRA21-1），as well as the rate of adverse drug reactions（ADRs） were compared between the 2 groups.Results： There was no statistical significance in remission rate and disease control rate，when comparisons were made between the 2 groups（P>0.05）.After treatment，CEA，CA125，NSE and CYFRA21-1 levels in the 2 groups were significantly lower than those before treatment（P<0.05）.There were no significant differences in CEA and CA125 levels，when comparisons were made between the 2 groups（P>0.05）.However，NSE and CYFRA21-1 levels in the patients of the nedaplatin group were significantly lower than those of the cisplatin group（P<0.05）.The rates of leucopenia，neutropenia，nausea and vomiting，constipation or diarrhea，increase of blood urea nitrogen or creatinine，and weight loss in the nedaplatin group were significantly lower than those in the cisplatin group（P<0.05）.Conclusion： Nedaplatin has similar efficacy as cisplatin in the treatment of inoperable locally-advanced NSCLC，with higher safety，meanwhile it could decrease the levels of NSE and CYFRA21-1.For this reason，it is worthy further clinical promotion.

Is consolidation chemotherapy after concurrent chemoradiotherapy beneficial for locally advanced non-small cell lung cancer? A pooled analysis of the literature.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 7000-7000 ◽  
Author(s):  
Satomi Yamamoto ◽  
Kazuyuki Tsujino ◽  
Masahiko Ando ◽  
Tomoya Kawaguchi ◽  
Akihito Kubo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Advanced Nsclc ◽  
Random Effect ◽  
Locally Advanced ◽  
Pooled Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Consolidation Chemotherapy ◽  
Locally Advanced Nsclc

7000 Background: There is a growing interest on the efficacy of maintenance chemotherapy to metastatic non-small cell lung cancer (NSCLC) and adjuvant chemotherapy to early stage NSCLC. However, the role of consolidation chemotherapy (CCT) after concurrent chemo-radiotherapy in locally advanced NSCLC is undetermined. Methods: We systematically searched PubMed for phase II/III trials examining survival of locally-advanced NSCLC treated with concurrent chemo-radiotherapy between January 1, 1995 and October 31, 2011. Median overall survival (mOS) and corresponding 95% confidence interval (CI) were collected from each study and pooled. We extracted log-transformated hazards and its standard errors under the assumption that survival follows an exponential distribution, and computed a pooled mOS and its 95% CI using random-effect model. Collected trial arms were divided into two groups by the presence of CCT: Arm with CCT (CCT+) and without CCT (CCT-). Results: Forty-five studies were identified including 9 phase III studies and 36 phase II studies with 51 arms (CCT+: 29, CCT-: 22). Clinical data were comparable in clinical stage, performance status, cancer histology, gender, and median age between the two groups. I2 values for assessing heterogeneity were 15.3, 9.1 and 24.2% in overall, CCT+ and CCT- studies, respectively. There was no statistical difference in pooled mOS between CCT+ (18.5 month, 95%CI: 16.7-20.5) vs CCT- (18.1 month, 95%CI: 16.5-20.2). In regard to the ≥ grade 3 toxicities in pneumonitis, esophagitis, and neutropenia, there was no difference between the two groups throughout the whole treatment courses. In random effect models, predicted hazard ratio of CCT+ to CCT- was 0.98 (95%CI: 0.8-1.13, p=0.7574). These models estimated that addition of CCT could not yield more than 3 months of survival prolongation for patients with locally advanced NCSLC. Conclusions: The pooled analysis on publication basis failed to provide evidence that consolidation chemotherapy yields significant survival benefit for locally advanced NSCLC.

scholarly journals Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: A phase Ⅱ clinical trial

2020 ◽  
Author(s):  
Zhixue Fu ◽  
Jun Liang ◽  
Yang Xu ◽  
Wenqing Wang ◽  
Deng Lei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Survival Time ◽  
Concurrent Chemoradiotherapy ◽  
Advanced Nsclc ◽  
Response Rate ◽  
Locally Advanced ◽  
Small Cell ◽  
Small Cell Lung ◽  
Locally Advanced Nsclc

Abstract Background: The objectives of this study were to determine the objective effective response rate, survival, and safety of radiotherapy combined with gefitinib in patients with locally advanced non-small cell lung cancer (NSCLC) who were unfit for surgery or concurrent chemoradiotherapy.Methods: The patients with the locally advanced NSCLC who were unfit to receive surgery or concurrent chemoradiotherapy, received thoracic intensity-modulated radiotherapy (IMRT) combined with gefitinib 250 mg daily.Results: Twenty-nine patients were enrolled between July 2014 and March 2017. Of the 29 patients, 21 (72.4%) experienced a partial response, 6 (20.7%) had stable disease, and 2 (6.9%) experienced progression of disease. The objective response rate was 72.4%, and the disease control rate was 93.1%. The median follow-up time was 51 months. The disease progression showed in 26 (89.7%) patients, including local progression in 20 (69.0%) and distant metastasis in 16 (55.2%). The median survival time (MST) and progression-free survival time (PFS) were 26 and 11 months, respectively. The 3-, 4-, 5-year survival rates were 37.6%, 29%, and 29%, respectively. The PFS rates were 17.2%, 9.2%, and 9.2%. Two patients developed grade 3 acute adverse events, and two patients developed grade 2 acute irradiation pneumonitis.Conclusions: For patients with locally advanced NSCLC who are not eligible for surgery or concurrent chemoradiotherapy, IMRT combined with gefitinib can improve the objective effective rate and is generally well-tolerated.

Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.

1997 ◽  
Vol 15 (4) ◽  
pp. 1409-1417 ◽  
Author(s):  
G Frasci ◽  
P Comella ◽  
G Scoppa ◽  
C Guida ◽  
A Gravina ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Advanced Nsclc ◽  
Locally Advanced ◽  
Small Cell ◽  
Hematologic Toxicity ◽  
Small Cell Lung ◽  
Antitumor Effects ◽  
Locally Advanced Nsclc

PURPOSE Both cisplatin (CDDP) and paclitaxel have shown good antitumor activity in non-small-cell lung cancer (NSCLC) patients and are able to potentiate the antitumor effects of radiation therapy (RT). This study aimed to determine the maximum-tolerated doses (MTDs) of CDDP and paclitaxel (escalated alternately) when given concurrently with RT and to define the nature of the dose-limiting toxicity (DLT). PATIENTS AND METHODS Chemotherapy-naive patients with locally advanced NSCLC received six weekly administrations of a CDDP-paclitaxel combination with concurrent local RT. The starting doses of CDDP and paclitaxel were 30 mg/m2/wk and 35 mg/m2/wk, respectively. RT was initially given at the dose of 1.2 Gy twice daily for 5 days per week for 5 weeks (total dose, 60 Gy) and at a single daily dose of 2 Gy for 5 days per week for 6 weeks in the last two cohorts of patients. The drug doses were escalated alternately until DLT occurred in more than one third of the patients in a given cohort. RESULTS Overall, 25 patients were recruited through five different cohorts. All were assessable for toxicity. Esophagitis was the main toxicity and occurred in 16 of 25 patients (64%) and was grade 3 or 4 in five of them. At step 3 (CDDP 35 mg/m2/wk and paclitaxel 45 mg/m2/wk), two of five patients had to discontinue treatment because of severe esophagitis and one of these died of complications related to grade 4 esophagitis. However, keeping the same doses of chemotherapy and replacing hyperfractionation with a standard single-day fraction, weekly doses of CDDP and paclitaxel of 35 mg/m2 and 45 mg/m2 could be safely administered. Neutropenia was by far the most relevant hematologic toxicity and occurred in 33 of 141 weekly delivered courses, but it was of grade 4 in only four courses. Substantial pulmonary or neurologic toxicity was not observed in this study. Two complete responses (CRs) and 13 partial responses (PRs) were observed, for a 60% overall response rate (95% confidence interval [CI], 39% to 79%). The median survival time was 16 months, with a 66% 1-year survival probability. CONCLUSION CDDP 35 mg/m2/wk and paclitaxel 45 mg/m2/wk can be safely administered with concurrent standard RT. The use of hyperfractionation is associated with a more frequent occurrence of severe esophagitis and requires a reduction of the CDDP dose to 30 mg/m2/ wk. Only future randomized trials will elucidate which of these two approaches (standard or hyperfractionated RT) is the better option to improve the outcome of patients with locally advanced NSCLC.

Surgical Treatment of Initially Unresectable Locally Advanced Non-small Cell Lung Cancer Following Tislelizumab Plus Chemotherapy: A Case Report

2021 ◽  
Author(s):  
Chen Huang ◽  
Yongmei Dai ◽  
Qianshun Chen ◽  
Feng Li ◽  
Xunyu Xu
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Advanced Nsclc ◽  
Combined Treatment ◽  
Locally Advanced ◽  
Small Cell ◽  
Stage Iiib ◽  
Small Cell Lung ◽  
Locally Advanced Nsclc

Abstract Background: Radical concurrent chemoradiotherapy is the preferred treatment for patients with stage IIIB non-small cell lung cancer (NSCLC), but the prognosis is poor. The emergence of immune checkpoint inhibitors has changed the treatment strategy for advanced NSCLC, providing new opportunities for therapy. However, neoadjuvant immunotherapy of locally advanced NSCLC is still in the exploratory stage. Case presentation: A 47-year-old male with stage IIIB squamous cell lung cancer with invasion of the pulmonary artery, left superior pulmonary vein (LSPV), and left atrium (LA) at diagnosis. The patient’s lesions were significantly reduced after four cycles of combined treatment with tislelizumab and carboplatin plus nab-paclitaxel, he then underwent successful left pneumonectomy with mediastinal lymph node dissection, and postoperative pathology showed a pathologic complete response (pCR). Conclusions: The findings demonstrated that chemotherapy in combination with immunotherapy can provide an opportunity for radical surgery in some patients with locally advanced NSCLC.

scholarly journals Evaluation of a prognostic scoring system based on the systemic inflammatory and nutritional status of patients with locally advanced non-small-cell lung cancer treated with chemoradiotherapy

2017 ◽  
Vol 59 (1) ◽  
pp. 50-57 ◽  
Author(s):  
Takamasa Mitsuyoshi ◽  
Yukinori Matsuo ◽  
Hitoshi Itou ◽  
Takashi Shintani ◽  
Yusuke Iizuka ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Nutritional Status ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Advanced Nsclc ◽  
Locally Advanced ◽  
Small Cell ◽  
Small Cell Lung ◽  
Skeletal Mass ◽  
Locally Advanced Nsclc

Abstract Systemic inflammation and poor nutritional status have a negative effect on the outcomes of cancer. Here, we analyzed the effects of the pretreatment inflammatory and nutritional status on clinical outcomes of locally advanced non-small-cell lung cancer (NSCLC) patients treated with chemoradiotherapy. We retrospectively reviewed 89 patients with locally advanced NSCLC treated with chemoradiotherapy between July 2006 and June 2013. Serum C-reactive protein (CRP) was assessed as an inflammatory marker, and serum albumin, body mass index (BMI) and skeletal mass index were assessed as nutritional status markers. The relationships between these markers and overall survival (OS) were assessed. The median OS was 24.6 months [95% confidence interval (CI): 19.4–39.3 months]. During follow-up, 58 patients (65%) had disease recurrence and 52 patients (58%) died. In multivariate Cox hazard analysis, CRP levels and BMI approached but did not achieve a significant association with OS (P = 0.062 and 0.094, respectively). Recursive partitioning analysis identified three prognostic groups based on hazard similarity (CRP-BMI scores): 0 = CRP &lt; 0.3 mg/dl, 1 = CRP ≥ 0.3 mg/dl and BMI ≥ 18.5 kg/m2, and 2 = CRP ≥ 0.3 mg/dl and BMI &lt; 18.5 kg/m2. The CRP-BMI score was significantly associated with OS (P = 0.023). Patients with scores of 0, 1 and 2 had median OS of 39.3, 24.5 and 14.5 months, respectively, and the scores also predicted the probability of receiving salvage treatment after recurrence. The CRP-BMI score is thus a simple and useful prognostic marker of clinical outcome for patients with locally advanced NSCLC treated with chemoradiotherapy.

Sign in / Sign up

Export Citation Format

Share Document